Trastuzumab administration associated with change in HER2 status

Area of Science:

• Oncology
• Clinical Trials
• Cancer Therapeutics

Background:

• Trastuzumab is a standard therapy for HER2/neu-positive early-stage breast cancer, significantly reducing recurrence and mortality.
• Controversy remains regarding optimal timing, duration, and use after disease recurrence in the adjuvant setting.

Observation:

• A patient with HER2/neu-positive stage I breast cancer received adjuvant trastuzumab therapy.
• The patient subsequently relapsed with metastatic disease that was HER2/neu-negative.

Findings:

• This case highlights a rare instance of trastuzumab resistance or loss of HER2/neu expression during disease progression.
• The patient's metastatic disease did not express the HER2/neu target, suggesting a potential mechanism for treatment failure.

Implications:

• This case underscores the need for further research into mechanisms of trastuzumab resistance in breast cancer.
• It prompts re-evaluation of treatment strategies and monitoring for HER2/neu status changes in patients with metastatic breast cancer.
• Understanding these dynamics is crucial for optimizing adjuvant and metastatic treatment protocols for HER2/neu-positive breast cancer.